Please use this identifier to cite or link to this item:
Title: Epithelial to mesenchymal transition regulates surface pd-l1 via cmtm6 and cmtm7 induction in breast cancer
Authors: Xiao, Malina
Hasmim, Meriem
Lequeux, Audrey
Van Moer, Kris
Tan, Tuan Zea 
Gilles, Christine
Hollier, Brett G.
Thiery, Jean Paul 
Berchem, Guy
Janji, Bassam
Noman, Muhammad Zaeem
Keywords: Breast cancer
CMTM family
Epithelial to mesenchymal transition
Immune checkpoints
Issue Date: 9-Mar-2021
Publisher: MDPI AG
Citation: Xiao, Malina, Hasmim, Meriem, Lequeux, Audrey, Van Moer, Kris, Tan, Tuan Zea, Gilles, Christine, Hollier, Brett G., Thiery, Jean Paul, Berchem, Guy, Janji, Bassam, Noman, Muhammad Zaeem (2021-03-09). Epithelial to mesenchymal transition regulates surface pd-l1 via cmtm6 and cmtm7 induction in breast cancer. Cancers 13 (5) : 1-Dec. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: CMTM6 is a critical regulator of cell surface expression of PD-L1 in tumor cells, but little is known about the transcriptional regulation of CMTM6. Here we report that the expression of CMTM6 positively correlates with the epithelial to mesenchymal transition (EMT) score in breast cancer cell lines and with the major EMT marker Vimentin in triple-negative breast cancers (TNBC). We showed that CMTM6 is concomitantly overexpressed with PD-L1 in breast mesenchymal compared with the epithelial cells. Driving a mesenchymal phenotype in SNAI1-inducible MCF-7 cells (MCF-7Mes cells) increased both PD-L1 and CMTM6. CMTM6 silencing in MCF-7Mes cells partially reduced cell surface expression of PD-L1, indicating that a proportion of the PD-L1 on the surface of MCF-7Mes cells depends on CMTM6. We also found a positive correlation between CMTM3 and CMTM7 expression with EMT score in breast cancer cells, and with Vimentin in TNBC patients. Dual knockdown of CMTM6 and CMTM7 significantly decreased PD-L1 surface expression in MCF-7Mes cells, indicating that both CMTM6 and CMTM7 regulate the expression of PD-L1. This study highlights the importance of CMTM6 and CMTM7 in EMT-induced PD-L1 and suggests that EMT, CMTM6 or CMTM7 modulators can be combined with anti-PD-L1 in patients with highly aggressive breast cancer. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Source Title: Cancers
ISSN: 2072-6694
DOI: 10.3390/cancers13051165
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_cancers13051165.pdf7.92 MBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons